John L. Marshall, MD, on Accessibility of Precision Medicine

Video

The expert from the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

In an article published in the journal Oncology®, John L. Marshall, MD, of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

“Cancer care can no longer be a luxury item, only for the rich. We must work toward wide access,” Marshall wrote. “Opening markets through collaborative science will secure the return on investment for our business partners, and secure our progress toward finding the cures for cancer.”

In an interview with CancerNetwork®, Marshall spoke about his paper further and why precision medicine will change global cancer care for decades to come.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

Marshall JL. The Prospective Incorporation of Molecular Profiling Will Transform Global Cancer Care. Oncology. https://www.cancernetwork.com/view/the-prospective-incorporation-of-molecular-profiling-will-transform-global-cancer-care

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content